

# MEASuRE: Metreleptin Effectiveness And Safety Registry

NCT02325674

---

**Status** RECRUITING  
**Sponsor** Amryt Pharma  
**Enrollment** 100 participants

## Key Eligibility Criteria

---

### Inclusion (3)

- Patients treated with metreleptin through commercial supply at the time or before enrolment into registry
- Patients who provide a written consent
- Patient coming off metreleptin clinical studies and continuing or restarting treatment with metreleptin through commercial supply

### Exclusion (1)

- Patients currently treated with an investigational agent as part of a clinical trial

## Locations (28 total)

---

University Alabama at Birmingham, Birmingham, Alabama, United States  
City of Hope, Duarte, California, United States  
Atlanta Diabetes Associates, Atlanta, Georgia, United States  
... and 25 more locations